Global Market Direct’s pharmaceuticals report, “BrainCells Inc. - Product Pipeline Review - 2013” provides data on the BrainCells Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, BrainCells Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from BrainCells Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
- BrainCells Inc. - Brief BrainCells Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of BrainCells Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of BrainCells Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the BrainCells Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate BrainCells Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of BrainCells Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the BrainCells Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with BrainCells Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of BrainCells Inc. and identify potential opportunities in those areas.
Table Of Contents
BrainCells Inc. - Product Pipeline Review - 2013 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 BrainCells Inc. Snapshot 4 BrainCells Inc. Overview 4 Key Information 4 Key Facts 4 BrainCells Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 BrainCells Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 BrainCells Inc. - Pipeline Products Glance 10 BrainCells Inc. Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Phase I Products/Combination Treatment Modalities 11 BrainCells Inc. - Drug Profiles 12 BCI-1038 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 BCI-1206 13 Product Description 13 Mechanism of Action 13 RandD Progress 13 BCI-1283 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 BrainCells Inc. - Pipeline Products by Route of Administration 15 BrainCells Inc. - Pipeline Products By Mechanism of Action 16 BrainCells Inc. - Recent Pipeline Updates 17 BrainCells Inc. - Dormant Projects 18 BrainCells Inc. - Discontinued Pipeline Products 19 Discontinued Pipeline Product Profiles 19 sabcomeline hydrochloride 19 BrainCells Inc. - Locations And Subsidiaries 20 Head Office 20 Financial Deals Landscape 21 BrainCells Inc., Deals Summary 21 BrainCells Inc., Pharmaceuticals and Healthcare, Deal Details 22 Venture Financing 22 BrainCells Raises Additional US$2 Million In Venture Financing 22 BrainCells Secures US$0.99 Million In Venture Financing 23 BrainCells Secures US$50 Million In Series B Financing 24 Licensing Agreements 27 Proximagen Group Enters Into Licensing Agreement With BrainCells 27 Taisho Pharma Enters Into Licensing Agreement with BrainCells 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables
BrainCells Inc., Key Information 4 BrainCells Inc., Key Facts 4 BrainCells Inc. - Pipeline by Indication, 2013 7 BrainCells Inc. - Pipeline by Stage of Development, 2013 8 BrainCells Inc. - Monotherapy Products in Pipeline, 2013 9 BrainCells Inc. - Phase II, 2013 10 BrainCells Inc. - Phase I, 2013 11 BrainCells Inc. - Pipeline By Route of Administration, 2013 15 BrainCells Inc. - Pipeline Products By Mechanism of Action, 2013 16 BrainCells Inc. - Recent Pipeline Updates, 2013 17 BrainCells Inc. - Dormant Developmental Projects,2013 18 BrainCells Inc. - Discontinued Pipeline Products, 2013 19 BrainCells Inc., Deals Summary 21 BrainCells Raises Additional US$2 Million In Venture Financing 22 BrainCells Secures US$0.99 Million In Venture Financing 23 BrainCells Secures US$50 Million In Series B Financing 24 Proximagen Group Enters Into Licensing Agreement With BrainCells 27 Taisho Pharma Enters Into Licensing Agreement with BrainCells 29
List of Figures
BrainCells Inc. - Pipeline by Indication, 2013 6 BrainCells Inc. - Pipeline by Stage of Development, 2013 8 BrainCells Inc. - Monotherapy Products in Pipeline, 2013 9 BrainCells Inc. - Pipeline Products By Mechanism of Action, 2013 16